The licensing cooperation (License-in and License-out) of pharmaceutical companies mainly involves drug patent licensing.
Among all technical fields, the pharmaceutical industry has the highest dependence on intellectual property rights. The protection of pharmaceutical intellectual property rights by domestic and foreign pharmaceutical companies also runs through the entire process of drug research and development.
Products need to be developed, and patents need to be developed in parallel or even first, and ultimately market profits can be achieved through the exclusivity of drug patents.
The basic principle of the patent application strategy is that product patents should be completed in the early stage, especially core patents related to compounds, so that comprehensive pharmacological and toxicological research can be carried out later. Method patents and use patents can be applied for in the later stages of new drug development.
In the discovery stage of active new compounds, patent applications mainly include compound patents (general formula compounds, specific compounds), which are the most valuable patents among new drug patents.
Along with the research on pharmacology and toxicology, patent applications at this stage begin to establish peripheral patents, including crystal form patents, active compound salts, esters, isomers, water or solvation patents, etc.
At this point, a patent pool for new compounds began to take shape.
In the clinical stage, with the deepening of clinical trials and the accumulation of test data, patent applications at this stage often include composition patents, various dosage form patents, process patents and usage patents, etc.
After a new drug is successfully launched, in order to further expand the exclusivity of the patent and extend the life cycle of the new drug, patent applications at this stage mainly focus on new composition patents, new dosage form patents, and new use patents.
The above are common patent application strategies at different research stages. The actual patent application process often overlaps. For example, process patents for new compounds can be applied for in preclinical research, clinical research, and after marketing. Generally speaking, it is a long-term and dynamic process.
Therefore, Weikang immediately applied for a new drug compound patent after its own successful trial, and continued to apply for a series of composition patents in the subsequent clinical stage. The patent application after the launch is still in preparation. In short, all patent applications are in progress. The drug approval process is proceeding steadily.
Only by owning this series of combined patent pools for new drugs can we engage in licensing cooperation with other companies.
Wei Kang carefully looked at the latest cooperation plans sent by Pfizer, Bayer and Johnson & Johnson after communication.
These three companies are of equal strength, and the plans they propose have the best conditions among the multinational giants.
Several others either have enough anti-cancer drugs of their own, or have recently acquired new pharmaceutical companies, or have undergone asset replacement and business adjustments, and are currently unable to provide more favorable conditions.
After Bayer's buyout price of 10 billion euros spread, Pfizer and Johnson & Johnson also updated their cooperation plans and added the buyout price. Although it is not as good as Bayer, the conditions in other aspects are also more favorable.
He analyzed the relevant information of these three companies and got a general understanding.
Bayer really wants to buy out this prescription, so the cooperation plan they proposed is more about spending money.
But Pfizer's Andre secretly revealed some information to Weicome that only the giant's insiders knew.
Bayer is also developing new broad-spectrum anti-cancer drugs. Some results have been achieved so far, but the clinical effects are not satisfactory. That’s why they are so eager to buy out the prescription. Maybe they want to buy it back and analyze it carefully. They will use a two-pronged approach to try their best. Develop this product on its own instead of in-depth cooperation with Sanqing.
Johnson & Johnson's anti-cancer drug product line is not large in scale, but its products are highly competitive. Since an anti-cancer drug for the treatment of soft tissue tumors that was previously developed at a huge cost was refused by the Eagle Country FDA for 6 years, they now urgently need a powerful star product to seize the market, so they are interested in the Sanqing broad-spectrum anti-cancer drug. The desire is also very strong.
As for Pfizer, its anti-tumor product line is very rich and there is no shortage of new drugs. However, in some treatment areas, their products rank low and lack competitiveness. Nowadays, relying on only one or two flagship products to compete with other pharmaceutical companies will be very disadvantageous in the long run. Therefore, it is imperative to win blockbuster products such as broad-spectrum anti-cancer drugs and never give up.
The summary is that although Johnson & Johnson and Pfizer are both powerful, they each have their own shortcomings. Overall, Pfizer is weaker and more sincere in long-term cooperation.
Think about it, Pfizer has a wide product line, but if it is not marketed, then when selling drugs, for the sake of sales, it will definitely be more willing to promote Sanqing drugs.
Johnson & Johnson is currently suffering setbacks, and its own drugs are also very strong. If their own anti-cancer drugs can be launched, they may not bother to develop the market for Sanqing.
As for Bayer, in Wei Kang's mind, it has been silently eliminated.
Wei Kang frowned and continued to analyze the two companies' licensing cooperation plans.
Johnson & Johnson’s plan is: an upfront payment of US$500 million, cumulative development and commercial milestone payments of no more than US$3 billion, and gradient royalties based on global net sales. The total transaction value is expected to be US$3.5 billion.
Pfizer's plan is: an upfront payment of US$500 million, and is eligible to receive up to US$2 billion in payments after reaching registration milestones, US$500 million in payments after reaching cumulative sales milestones, and future sales in authorized territories.
At first glance, the amounts of the two plans seem to be about the same, and Johnson & Johnson even gives a little more money.
However, Johnson & Johnson subsequently provided a gradient royalty fee based on global net sales, while Pfizer provided a sales share in authorized regions.
Wei Kang actually mainly wants to sell drugs in Eagle Country and other developed countries, because he can't get involved in these places, and Chinese companies are easily targeted.
However, there are still a large number of third world developing countries on this planet. China's companies are still relatively strong in these places, and they do not want to give up most of the market easily.
Pfizer is not so greedy in comparison. It only agrees to sell in developed countries involved in the authorization. The two parties will jointly develop the market in these countries, and Pfizer will be responsible for the registration application and carry out commercial activities after approval.
In addition, Sanqing Pharmaceutical can jointly sell products in other developed countries outside of Eagle Country and share sales revenue, part of which will be provided by Pfizer.
So, which one has a better plan, the results are already coming out.
Of course, this is also based on Sanqing’s ambitions for the global market. If Sanqing only wants to collect money and has no intention of developing the market with its partners, then Johnson & Johnson’s plan is also a good choice. You only need to sit back and collect money. Can.
Wei Kang then looked at the list of discarded prescriptions attached to the cooperation plans of various pharmaceutical companies.
This is why Pfizer completely impressed Weikang.
Johnson & Johnson is similar to other pharmaceutical companies. It comes with more than a dozen abandoned prescriptions, ranging from anti-tumor drugs, AIDS treatment, anti-thrombosis, and even wound care prescriptions.
And in accordance with Wei Kang's requirements, the side effects that have been discovered and detailed data are marked.
But Wei Kang guessed that they should have concealed the side effects, because some drugs had not serious side effects and were canceled anyway.
Of course, there is another possibility, that is, the drug treatment effect is too poor or even ineffective, so it is abandoned.
This kind of prescription is useless to others, but in Wei Kang's hands, it can turn waste into treasure.
As long as the toxicology test and human tolerance are passed, Wei Kang can extract new specific drugs from the side effects, even if the original research and development direction is ineffective.
However, there are also many drugs that have relatively useless side effects, such as irritation to internal organs. Although some emetics and diarrhea drugs can also be extracted, the market for these drugs is not large and their effects are not important. There are also many types of existing drugs. Not much money to be made.
Only drugs that can treat fatal diseases are the real gold mines that can make pharmaceutical companies rich.
From these abandoned prescriptions, we can also see the main research and development directions of major pharmaceutical companies.
Every pharmaceutical company has made significant investments in anti-cancer drugs, and of course they are targeting different areas.
Such as blood cancer, lung cancer, lymphoma, melanoma, etc.
There are also many abandoned prescriptions in other research and development directions, including basically all aspects related to human organs.
These prescriptions dazzled Wei Kang, and they contained some side effects that made him excited.
He decided to have a good talk with these pharmaceutical companies. They were already here anyway, so why not package them all together and sell them to him?
Anyway, these discarded prescriptions are all carefully selected by various companies and are useless waste.
Pfizer’s list of abandoned prescriptions is particularly eye-catching because there are so many.
It seems that after this company learned that he likes to collect discarded prescriptions, it followed suit and packaged and sent discarded new drug formulas from the headquarters laboratory and even the laboratories of all acquired and merged pharmaceutical companies.
There must be some hard work from Andre.
It deserves to be the number one pharmaceutical company in the world.
What is a multinational pharmaceutical giant!
This is!
Hundreds of discarded prescriptions!
Just like that, it was all packed and delivered.
Although the categories are very narrow, there are also over-the-counter remedies for itchy skin, cough drops, eye drops and the like.
But Wei Kang didn't care, he just wanted to hug Dr. Andre and thank him for his assist.
It’s so thoughtful!
